Moleculin Biotech, (NASDAQ:MBRX) spotted trading -83.49% off 52-week high price. On the other end, the stock has been noted 61.02% away from the low price over the last 52-weeks. The stock changed 29.99% to recent value of $0.52. The stock transacted 15333452 shares during most recent day however it has an average volume of 956.62K shares. The company has 57.23M of outstanding shares and 46.32M shares were floated in the market.
On March 17, 2020, Moleculin Biotech, (NASDAQ:MBRX) a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, disclosed that it has entered into an agreement with the University of Texas Medical Branch at Galveston (UTMB) to conduct research on Moleculin’s patented portfolio of molecular inhibitors, including drug candidate, WP1122, for antiviral properties against a range of viruses, including Coronavirus. UTMB’s Center for Biodefense and Emerging Infectious Diseases collaborates with the Galveston National Laboratory, which is funded by NIAID, the U.S. Department of Defense, the U.S. Centers for Disease Control & Prevention and other federal agencies, as well as academic partners, private foundations, and the biopharmaceutical industry.
Published research has revealed that viral replication can be highly dependent on specific monosaccharides and has demonstrated the effectiveness of a compound known as ‘2-DG,’ a dual decoy of glucose and mannose, in the treatment of certain viruses1, commented Walter Klemp, Moleculin’s Chairman and CEO. And, this is rooted in an emerging field of research focused on the role of glycolysis and glycosylation, or more specifically, on glucose and mannose metabolism in viral activity, including the coronavirus2. Importantly, although 2-DG has shown promise in the laboratory in relevant in vivo models, its potential as a therapy is severely limited by its lack of drug-like properties, including circulation time and organ uptake. Our drug candidate, WP1122, is a prodrug of 2-DG (2-deoxy-D-glucose) that, based on recently developed preclinical data appears to overcome 2-DG’s lack of drug-like properties and is able to significantly increase tissue/organ concentration.
Its earnings per share (EPS) expected to touch remained 13.20% for this year.
According to the most recent quarter its current ratio was 1.7 that represents company’s ability to meet its current financial obligations. The price moved ahead of -19.57% from the mean of 20 days, -34.20% from mean of 50 days SMA and performed -49.45% from mean of 200 days price. Company’s performance for the week was -7.95%, -31.57% for month and YTD performance remained -43.16%.